Ligand Pharmaceuticals

LGND | NASDAQ | 0 Obserwujący

$102.19

+1.27%

$1.28

Obserwuj

Overview Metrics Financials

Fair Price

$07.20

Overvalued by 64.5%

Aby wyświetlić sprawiedliwą cenę akcji, musisz być członkiem Bulios Black.

Profile

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a San Diego-based biopharmaceutical company specializing in the development and acquisition of technologies that support the discovery and development of new therapeutics. The company generates revenue by licensing its Captisol® platform to biotech partners and manages a diversified portfolio of over 100 licensed programs across various therapeutic areas and development stages. In July 2024, Ligand announced the acquisition of APEIRON Biologics AG for $100 million, securing royalty rights to the commercial oncology drug QARZIBA®, designed for the treatment of high-risk neuroblastoma. Financial results for the second quarter of 2024 showed revenues of $41.5 million, surpassing analysts' expectations. The company plans to release its fourth quarter and full-year 2024 financial results on February 27, 2025.

Feed

There are no posts to show right now.

Ligand Pharmaceuticals

Fair Price

Profile

Feed

Zaloguj się do Bulios

Utwórz profil Bulios

Dlaczego Bulios?